- News & Events
- About Us
- Find a Physician
- Make a Gift
Community Regional Medical Center is among 10 facilities selected to participate in a national study to test the success of CyberKnife® in treating lung tumors.
Standard lung cancer treatment involves either surgery or a combination of radiation therapy and chemotherapy. Although radiation and chemotherapy can have positive effects, they are unlikely to cure this type of cancer.
The state-of-the-art CyberKnife® stereotactic radiosurgery system is a new type of technology that uses a unique image-guided system to precisely focus large doses of X-rays on the tumor, remaining accurate even if the patient moves during the procedure.
The Regional Medical Center is the first in the world to use CyberKnife® G4 (Generation 4) technology.
The patient benefits of the new procedure include:
“It’s a fantastic, state-of-the-art technology, which will become the future methodology for treatments,” said Dr. Douglas Wong, the principal radiation oncologist conducting the study at the Regional Medical Center.
The purpose of this study is to see if this treatment will help patients with early stage non-small cell lung cancer and to evaluate the effect of the treatment on their quality of life over time.
“Many physicians are still unaware of CyberKnife®’s broad clinical applications,” said Dr. Wong in a recent issue of Bay Area Oncology News.
Treatment is given between three and 21 days, and patients are monitored by the study doctor at specific intervals over the next two years, and then yearly.
Facilities participating in the study include:
Eddie Hughes reported this story.. He can be reached at MedWatchToday@CommunityMedical.org.